What stopping GLP-1 medicines means for heart health
People stopping GLP-1 medicines may gradually lose improvements in weight and cardiovascular risk factors when treatment ends, a Mumbai cardiologist has warned. Dr Parin Sangoi, a consultant interventional cardiologist at Wockhardt Hospitals, Mumbai Central, told The Indian Express that this does not mean stopping will immediately cause a heart attack.
His distinction is between an immediate event and a change in health over time. As the medicine’s effects diminish, weight can return, blood sugar and blood pressure can rise, and metabolic health can deteriorate. Together, those changes may increase cardiovascular risk.
The warning is particularly relevant to people prescribed these medicines for type 2 diabetes or obesity, and to those who already have cardiovascular disease. It is advice about planning the end of treatment, rather than evidence that discontinuation itself triggers a sudden cardiac emergency.
How GLP-1 treatment affects cardiovascular risk
GLP-1 medicines act on pathways involved in appetite and blood sugar regulation. They are used to treat type 2 diabetes and obesity, although individual medicines have different approved uses. Some have also been shown to reduce cardiovascular risk in particular patient groups.
Sangoi pointed to studies involving semaglutide that found fewer major cardiovascular events while patients were receiving treatment. That evidence should not be read as a promise that the same protection will remain after the medicine is withdrawn.
There are two separate questions here: whether the improvements in weight and metabolic health persist, and whether protection against events such as heart attacks continues. According to Sangoi, evidence suggests that stopping weight-management medicines can bring substantial weight regain and reverse some cardiometabolic improvements. Long-term evidence about cardiovascular protection after discontinuation is more limited.
The report gives no estimate of how much weight an individual might regain, how quickly their risk factors might change, or the size of any subsequent increase in heart risk. The uncertainty surrounding what follows treatment is also the subject of research into GLP-1 weight regain.
Dr Sangoi urges patients to plan before stopping
Sangoi advised patients not to discontinue treatment on their own initiative. The reason the medicine was prescribed matters: someone with diabetes may need a plan for rising blood sugar, while someone treated for obesity may need help managing returning weight.
For a patient with established cardiovascular disease, the discussion should also consider whether another treatment is needed to manage their risk factors. Sangoi said that the extent of any continuing protection differs between individuals; clinical attention should therefore remain on weight, blood sugar, blood pressure and cholesterol.
Side effects, cost, pregnancy plans or another medical reason may prompt a conversation about stopping. Depending on the circumstances, he said, the prescribing doctor can assess whether to change the dose, introduce another medicine or arrange closer monitoring. These are individual clinical decisions, not interchangeable options for every patient.
That makes the conversation broader than whether to take the next injection. It can require a review of GLP-1 treatment alongside other medicines, with attention to the conditions that still need managing.
Monitoring after GLP-1 treatment ends
After discontinuation, Sangoi recommended regular checks of weight, blood pressure, blood sugar and other cardiovascular risk factors so that changes can be identified early. The report does not specify a universal testing schedule or a standard replacement treatment.
The remaining evidence gap concerns how much cardiovascular protection persists, and for how long, once treatment has stopped. Until that is better understood, the practical task is to preserve the measurable improvements on which heart health depends, with a plan agreed before the prescription ends.
